Overview

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%
Phase:
Phase 4
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Ophthalmic Solutions
Tetrahydrozoline
Travoprost